NCT05604417View on ClinicalTrials.gov

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2026

Conditions
Relapsed Follicular LymphomaRefractory Follicular Lymphoma
Interventions
DRUG

TAZEMETOSTAT

Dosage and treatment timings per protocol

DRUG

Zandelisib

Dosage and treatment timings per protocol

Sponsors

Collaborators (1)

MEI Pharma, Inc.
All Listed Sponsors
collaborator

MEI Pharma, Inc.

INDUSTRY

lead

Jacob Soumerai, MD

OTHER